Vicore Pharma Holding AB (VCRE) FinancialsVCREVicore Pharma Holding AB

Evaluating the bottom line, Vicore Pharma Holding AB maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6782.83%, while the net margin is -6454.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VCRE converts its operational activities into shareholder value.

In the context of the broader market, VCRE competes directly with industry leaders such as VRDN and SUPN. With a market capitalization of $265.74M, it holds a significant position in the sector. When comparing efficiency, VCRE's gross margin of 100.00% stands against VRDN's 100.00% and SUPN's 88.09%. Such benchmarking helps identify whether Vicore Pharma Holding AB is trading at a premium or discount relative to its financial performance.

The gross margin has been consistently high at 100% for the last four quarters, indicating strong revenue generation relative to costs, despite significant net losses.